Max Nisen, Columnist

Evidence of Biotech Froth Continues to Mount

Investors keep driving up shares based on shaky trial data.

October 4, 2017 at 4:38 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

Biotech investors may need to pump the brakes.

Share prices have been soaring; the Nasdaq Biotech Index is up 28 percent this year. Drug failures are being punished more modestly. And now the definition of drug success appears to be getting more generous.